Portfolio Receipts of $742 million in Q4 2024 and $2,801 million for FY 2024Royalty Receipts growth of 12% in Q4 2024 and 13% for FY 2024 Net cash provided by operating activities of $743 million in ...

AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...

Johnson & Johnson may outshine AbbVie as a top defensive stock pick. Read how Ben Graham's framework evaluates each ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

AbbVie Inc. closed 5.34% below its 52-week high of $207.32, which the company reached on October 31st.

Full Year 2024 Results Key Financial Results Revenue: US$56.3b (up 3.7% from FY 2023). Net ...

AbbVie holds a strong portfolio of marketed and ... Imbruvica's strong clinical data in several forms of blood cancer led to peak sales above $5 billion, but increasing competition has led to ...

The information for this article is based on a press release statement and InvestingPro data, where investors can access a comprehensive Pro Research Report covering AbbVie's detailed financial ...

$310.4 billion "2024 was a year of significant progress for AbbVie. Our growth platform delivered outstanding results, we advanced our pipeline with key regulatory approvals and promising data ...